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PHARMACEUTICAL INNOVATION: DEFINITION, AND MECHANISMS FOR
REWARD
Hughes D
Bangor University, Bangor, UK
OBJECTIVES: To define the concept of pharmaceutical innovation, examine
whether it merits reward, and identify mechanisms for its incentivisation.
METHODS:Whether or not a medicine is innovative dependents on its novelty and
the benefits it generates. Novelty requires something new, original and perhaps
ingenious and is a necessary, but not sufficient, requirement for innovation. Novel
pharmaceutical attributes include: new target of pharmacological mechanism of
action, new chemical structure, improved formulation, improved pharmacokinet-
ics and efficient methods of production. Benefits depend on perspective. Whereas
a patient would value health-related quality of life, life expectancy, safety and
convenience, payers of healthcare (e.g. UK NHS) may legitimately value population
health and cost-effectiveness. A society might additionally value non-health ben-
efits such as attracting pharmaceutical company investment in skilled jobs, and
social responsibility (e.g. environment, neglected diseases). RESULTS: An effective
vaccine developed in the UK against malaria would be considered highly innova-
tive from a societal perspective, but not from an NHS perspective, as malaria does
not affect NHS patients. CONCLUSION: Health benefits to NHS patients are already
rewarded to (and in some cases beyond) the threshold for cost-effectiveness
(£30,000 per QALY). There is no incentive for paying an additional premium. How-
ever, where benefits of innovation to society exceed the costs, there is an argument
for reward. This should not be through price increases, but through taxation and
patent laws. The Patent Box, which will decrease the corporation tax to 10% on
profits from UK patents, is one such mechanism. Alternatively, a ‘value-based
patenting’ scheme might vary patent duration according to the benefits achieved,
as the clinical evidence matures from the time of licensing. This might benefit
patients through the earlier introduction of generics when branded products are
mediocre, reward genuinely innovative products, while still allowing the introduc-
tion of ‘me-toos’ to compete on price.
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Measuring “outcomes” is at the heart of this Society’s mission and of efforts to
improve health and health care delivery. Despite this central role, there is no com-
mon agreed-upon definition as to what is meant by outcomes. For example, for
some commentators, outcomes refer uniquely to quality-of-life and survival of
individual patients; this thinking underlies the US Patient Centered Outcomes Re-
search Institute. For others, including those doing economic evaluation, outcomes
may refer to the average health benefit groups of patients. Yet others use “out-
comes” to refer to aspects of functioning of the health care system. This lack of
consistency does little to illuminate the challenges in equitably delivering timely,
high quality, and affordable health care. In this presentation, the authors present a
typology of outcomes for health research along with and relevant examples. At the
most granular level, endpoints in randomized trials are often clinical outcomes
which are characterized as immediately observable - “hard” - such as hospitaliza-
tion, death or functional status, or latent - “soft” - such as quality-of-life, pain, or
satisfaction. At the next level are health outcomes which are the results of care
delivered in actual practice and can be subdivided into: treatment outcomes which
reflect the intended and unintended medical consequences of undergoing therapy
and patient outcomes which reflect the impact on patients of undergoing care in
the real world. System outcomes can be thought of as the impact of delivering care
to a group of patients and are measures of the degree of functionality of the health
care system. At the highest level are societal outcomes, which measure the impact
of health on the wellbeing of society. Consensus as to what is meant by “outcomes”
would be an important step towards improving the quality of the discourse and
critical thinking in this area.
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OBJECTIVES: The objective of this study is to examine the potential impact of
recent reform in anti-rebate law of drugs in South Korea.METHODS: It has been an
old business practice that some doctors and pharmacists receive financial benefits
from pharmaceutical companies and distributors in exchange for business favors
in Korea. These kickbacks are considered ‘unethical and illegal drug rebates’. The
Korea Fair Trade Commission reckoned consumer damage caused by illegal re-
bates in the medicines market at about US$2.02 billion, accounting for about 20% of
total pharmaceutical sales in the year of 2007. There are a couple of reasons why
illegal drug rebate is so prevalent in Korea. First, the current drug pricing system
guarantees relatively good prices for generic products which local companies focus
on producing. Good prices tend to leave rooms for marketing and illegal rebates. On
top of that, there are lots of small scale suppliers relative to the pharmaceutical
market size of Korea. Fierce competitions among drug suppliers make them con-
centrate on marketing activities, often coupled with illegal rebates. Third, govern-
ment has no control over the visits by drug company representatives to doctors’
offices. In addition, almost no medical treatment guidelines which could effec-
tively regulate doctor’s prescription behavior exist. RESULTS: Previously, any ille-
gal marketing practice by drug companies led to criminal punishment of drug
companies alone, leaving doctors and pharmacists untouched. Under the new leg-
islation, punishment for illegal rebate is now extended to doctors and pharmacists.
By penalizing both rebate givers and receivers, it is hoped that the level of illegal
rebate can be disappeared or substantially reduced from the Korean market. How-
ever, we need to see what might happen in the real market practices from now on.
CONCLUSIONS: Remaining issues with this anti-rebate reform will be explored in
this study.
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Kirpekar S, Mallinson M
Double Helix Consulting, London, UK
OBJECTIVES:Manufacturers are under increasing pressure to conduct shorter clin-
ical trials in order to bring products to market as soon as possible and ensure
revenue maximisation before loss of exclusivity. At the same time, authorities
from markets across the globe have demonstrated increased interest in post-mar-
keting real-life clinical data in order to help make decisions with regards to reim-
bursement of drugs as well as their positioning in the treatment pathway.
METHODS: Manufacturers are spending increasing proportion of their budgets to
produce this post-marketing clinical data. It is important to ensure if the data that
is being produced is close to the needs of the payers. In majority of instances, it is
seen that the data being created is quite far from the expectations of authorities to
whose benefit it is being created. The data is typically considered for use in payer
discussions only at the end of the clinical study when little flexibility is possible in
the end-points and outcomes that will be demonstrated. Also, benefits such as
considering early data cuts to present on-going benefit of this long term data is not
usually seen. RESULTS: ; Market access, outcomes research and medical affairs
teams tend to function independently with very little collaboration as a result of
differing targets and budgets. This has made it difficult to have early payer-fo-
cussed input into clinical studies. This is particularly so if they are post-marketing
studies involving teams with lower focus on payer needs compared to peri-launch
market access teams. There is an increased need for greater cross-functional effort
on producing clinical data to ensure efficient use. CONCLUSIONS: Involving an
external market access agency that is able to advise on the production, analysis
and use of post-marketing clinical data is seen to be the solution to this issue.
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TELL ME WHO YOUR FRIENDS ARE: “PEERS” IN COMPARING HEALTH CARE
SYSTEMS
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Total health spending and its share in the social product have been staple indica-
tors in assessing and comparing health care systems. Comparison of health care
systems based on Euros and cents is limiting, however, since the health care sys-
tem is not an artifact of the economy. Institutions shape societal values on health
care leading to peculiarities even among health care systems that share traditions
in terms of health care financing and delivery. This paper presents a framework to
compare health care systems in a meaningful way that accounts for systemic
differences and similarities using the empirical technique cluster analysis. The
analysis will follow a three-step procedure. A review of the literature will be con-
ducted to identify major institutional indicators of any given health care system.
Cluster analysis will then be employed using these indicators based on data of
OECD member countries. Based on the isolated clusters using the “minimum de-
scription length” approach, “peer” health care systems will be identified and de-
scribed highlighting so-called leaders of the pack. At the heart of the performance
of every health care system is the extent to which it is able to respond to the desire
for a healthy life by members of society. This implies accounting for both efficiency,
which investigates the link between the link between health care resources and
health outcomes, and effectiveness, which assesses the achievement of goals
rather than choosing one over the other. Assessing health care systems against
peers and over time would not only set systems apart given their shared intent of
ensuring health by providing health care but may well engender learning and lead
to a race to the top.
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Increased health care spending across developed nations, including the US, has put
pressure on both public and private payers. The current literature has attributed
this growth in spending as being largely due to technological change. To prioritize
adoption of new technologies, so called cost-effectiveness analysis has been used
as the main tool by third-party payers and, as a result, has generated perhaps the
largest sub-field within health economics. In this paper we argue utilization of
cost-effectiveness analysis is subject to a form of Lucas critique; the stated goals of
the policy will not materialize when those affected by it respond to it. In particular,
we stress that cost-effectiveness analysis by payers invariably reflects prices set by
producers rather than resource costs used to produce treatments. This implies that
the “costs” in cost-effectiveness assessments depend on endogenous markups
which are, in turn, influenced by demand factors of patients, doctors, and, most
importantly, the cost-effectiveness policy used by payers to translate prices to
adoption decisions. We argue this has two important implications. First, under
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